Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.77 |
| ▸ | MAOB | P27338 | 1/20 | 0.77 |
| ▸ | CALML3 | P27482 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24142406 | 0.95 | MAOA (0.76) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL24142423 | 0.94 | MAOA (0.74) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL26735069 | 0.92 | MAOA (0.76) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL6625769 | 0.92 | MAOA (0.81) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL24142407 | 0.90 | MAOA (0.73) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL24142424 | 0.89 | MAOA (0.79) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL1986105 | 0.89 | MAOA (0.84) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL1380212 | 0.89 | MAOA (0.84) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL3060525 | 0.89 | MAOA (0.84) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL24142416 | 0.89 | MAOA (0.87) | MAOAMAOBCALML3CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348447-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | MAOA 4398/4885MAOB 4248/4885CALML3 1992/4885 |
| US-20230348447-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | MAOA 1751/4885MAOB 1216/4885CALML3 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.